Healthcare Services

Global Glioblastoma Multiforme Market Forecast 2026–2035 Presenting Long-Term Industry Expansion Insights

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Glioblastoma Multiforme Market By 2030 Starting From Its 2026 Size?

The glioblastoma multiforme market has shown significant expansion in recent years. It is forecast to increase from $2.7 billion in 2025 to $2.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.1%. Historically, this growth was driven by factors such as limited treatment options, advancements within neuro-oncology, the standardization of chemotherapy, the proliferation of cancer research centers, and improvements in imaging technologies.

The market for glioblastoma multiforme is projected to experience substantial expansion in the coming years, with its valuation anticipated to reach $3.94 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.8%. Key factors contributing to this projected growth include the innovation of new targeted medications, an increase in immunotherapy research, the uptake of personalized cancer therapies, enhanced financial support for brain cancer studies, and a greater emphasis on improving patient survival rates. Significant trends expected during this period involve a heightened concentration on targeted cancer treatments, the increasing implementation of multi-modal therapeutic strategies, the broadening scope of precision oncology investigations, the wider integration of sophisticated imaging diagnostics, and improved engagement in clinical trials.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Glioblastoma Multiforme Market?

The glioblastoma multiforme market is anticipated to be driven by the increasing prevalence of brain disorder cases. A brain disorder is defined as a condition affecting the brain’s structure or function, resulting in cognitive, emotional, or physical challenges. The escalation in brain disorder cases is attributable to elements like aging populations, longer life expectancies, lifestyle choices, and improved diagnostic capabilities. Gaining insights into brain disorders aids in advancing research on glioblastoma multiforme (GBM), fostering better early detection, innovative therapies, and improved patient results. By studying various neurological conditions, scientists are able to uncover genetic and molecular connections that contribute to GBM development. For example, in February 2025, according to Dementia Australia, an Australia-based non-profit organization, an estimated 433,300 Australians are living with dementia, with this figure projected to rise to 812,500 by 2054. Additionally, younger-onset dementia affects around 29,000 people in 2025, with projections indicating an increase to 41,000 by 2054. Consequently, the rising instances of brain disorders will propel the growth of the glioblastoma multiforme market.

Which Segment Categories Define The Glioblastoma Multiforme Market?

The glioblastoma multiforme market covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

What Trends Are Projected To Affect The Glioblastoma Multiforme Market?

Major companies engaged in the glioblastoma multiforme market are concentrating on the development of advanced therapies, such as CAR T-cell therapies, to meet the unmet medical needs associated with aggressive cancer. CAR T-cell therapies are a form of immunotherapy that involves genetically modifying a patient’s T-cells to more effectively target and eradicate cancer cells. For example, in June 2023, Chimeric Therapeutics Limited, an Australia-based biotech firm, initiated a Phase IB clinical trial for its CHM 1101 (CLXT CAR T) therapy for individuals with recurrent or progressive glioblastoma multiforme (GBM). The trial, which is being conducted across multiple centers, aims to assess the therapy’s safety and efficacy while also determining the appropriate Phase 2 dose. Initial results from Phase 1a demonstrated disease stability, and the current trial will build upon these findings to support further development. The company plans to use the collected data to inform the design of a registration trial and seek feedback from regulatory authorities.

Who Are The Top Companies Competing In The Glioblastoma Multiforme Market?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

Read the full glioblastoma multiforme market report here:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Which Regions Are Projected To Dominate The Glioblastoma Multiforme Market In The Coming Years?

North America was the largest region in the glioblastoma multiforme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Glioblastoma Multiforme Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21191&type=smp

Browse Through More Reports Similar to the Global Glioblastoma Multiforme Market 2026, By The Business Research Company

Minimally Invasive Glaucoma Surgery Migs Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/minimally-invasive-glaucoma-surgery-migs-devices-global-market-report

Eye Melanoma Global Market Report

https://www.thebusinessresearchcompany.com/report/eye-melanoma-global-market-report

Optic Atrophy Management Global Market Report

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795